CorMatrix Cardiovascular Receives European Community and U.S. Patent Claim Allowances for Polymer Drug Delivery Prostheses

CorMatrix Cardiovascular, Inc., today announced European Patent Office patent claim allowances for European Community (EC) Patent Application Nos. 15 902 462.9 and 15 886 687.1, and U.S. Patent and Trademark Office patent claim allowance for U.S. Patent Application No. 16/531,263, which are directed to synthetic polymer drug delivery prostheses comprising unique biodegradable, non-inflammatory poly(glycerol sebacate) (PGS) particulate, and sheet structures.

CorMatrix Cardiovascular notes, the degradable polymer drug delivery prostheses are adapted to administer various drugs, such as antibiotics and anti-inflammatories, and biologically active agents, such as growth factors, to target tissue.

The European and U.S. Patent allowances will further enhance CorMatrix’s growing synthetic polymer and ECM (Extracellular Matrix) delivery platforms, which, in addition to PGS, includes poly(urethane urea), polylactide (PLA), poly(e-caprolactone) (PCL) and polyglycolide (PLGA) compositions and structures.

CorMatrix’s current synthetic polymer and ECM delivery platforms comprise over one-hundred and twenty (120) issued U.S. and foreign patents, and over thirty (30) pending U.S. and foreign patent applications.

“As a cardiovascular regenerative company, the addition of various polymers to our portfolio will substantially add to the breadth and latitude of our capabilities. Future devices from CorMatrix will be combinations of our substantial ECM capabilities and beneficial polymers also directing them additionally towards drug delivery,” said Robert Matheny, MD, Chief Scientific and Medical Officer of CorMatrix Cardiovascular.

Doug Boyd, MD, Chief of Cardiovascular Surgery at East Carolina University Medical Center added, “Several companies are using biodegradable polymers with drugs attached to deliver a localized vascular effect. You can see this in the vascular stenting business and drug-coated balloons to prevent restenosis. These patents will allow for the development of these devices for open and percutaneous surgeries for all kinds of heart and vascular diseases.”

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.